{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:55:58Z","timestamp":1773687358353,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40291-022-00581-7","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T17:03:08Z","timestamp":1649178188000},"page":"333-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies"],"prefix":"10.1007","volume":"26","author":[{"given":"Pratibha","family":"Bhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila C.","family":"Schenkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin D.","family":"Hedley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Kerkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Broadbent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anargyros","family":"Xenocostas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Chin-Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bekim","family":"Sadikovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","volume":"8","author":"U Bacher","year":"2018","unstructured":"Bacher U, Shumilov E, Flach J, Porret N, Joncourt R, Wiedemann G, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018;8:113.","journal-title":"Blood Cancer J"},{"key":"581_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","volume":"130","author":"J Taylor","year":"2017","unstructured":"Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130:410\u201323.","journal-title":"Blood"},{"key":"581_CR3","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.clml.2017.02.015","volume":"17S","author":"U Patel","year":"2017","unstructured":"Patel U, Luthra R, Medeiros LJ, Patel KP. Diagnostic, prognostic, and predictive utility of recurrent somatic mutations in myeloid neoplasms. Clin Lymphoma Myeloma Leuk. 2017;17S:S62.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"581_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40291-019-00443-9","volume":"24","author":"F Yang","year":"2020","unstructured":"Yang F, Anekpuritanang T, Press RD. Clinical utility of next-generation sequencing in acute myeloid leukemia. Mol Diagn Ther. 2020;24:1.","journal-title":"Mol Diagn Ther"},{"key":"581_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391.","journal-title":"Blood"},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MOH.0000000000000562","volume":"27","author":"DM Swoboda","year":"2020","unstructured":"Swoboda DM, Gesiotto Q, Sallman DA. Novel therapies in myelodysplastic syndromes. Curr Opin Hematol. 2020;27:58.","journal-title":"Curr Opin Hematol"},{"key":"581_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32904","author":"WG Blum","year":"2020","unstructured":"Blum WG, Mims AS. Treating acute myeloid leukemia in the modern era: a primer. Cancer. 2020. https:\/\/doi.org\/10.1002\/cncr.32904.","journal-title":"Cancer"},{"key":"581_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ejh.13272","volume":"103","author":"MA Levy","year":"2019","unstructured":"Levy MA, Santos S, Kerkhof J, Stuart A, Aref-Eshghi E, Guo F, et al. Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies. Eur J Haematol. 2019;103:178.","journal-title":"Eur J Haematol"},{"key":"581_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19:4.","journal-title":"J Mol Diagn"},{"key":"581_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjh.16175","volume":"188","author":"L Palomo","year":"2020","unstructured":"Palomo L, Ib\u00e1\u00f1ez M, Ab\u00e1igar M, V\u00e1zquez I, \u00c1lvarez S, Cabez\u00f3n M, et al. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2020;188:605.","journal-title":"Br J Haematol"},{"key":"581_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jmoldx.2018.07.002","volume":"20","author":"RF McClure","year":"2018","unstructured":"McClure RF, Ewalt MD, Crow J, Temple-Smolkin RL, Pullambhatla M, Sargent R, et al. Clinical significance of DNA variants in chronic myeloid neoplasms: a report of the Association for Molecular Pathology. J Mol Diagn. 2018;20:717.","journal-title":"J Mol Diagn"},{"key":"581_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","volume":"35","author":"JA Kennedy","year":"2017","unstructured":"Kennedy JA, Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol. 2017;35:968.","journal-title":"J Clin Oncol"},{"key":"581_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424.","journal-title":"Blood"},{"key":"581_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1586\/ehm.12.45","volume":"5","author":"A Walker","year":"2012","unstructured":"Walker A, Marcucci G. Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. Expert Rev Hematol. 2012;5:547.","journal-title":"Expert Rev Hematol"},{"key":"581_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/MAJ.0b013e318201109d","volume":"341","author":"TL Lin","year":"2011","unstructured":"Lin TL, Smith BD. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. Am J Med Sci. 2011;341:404.","journal-title":"Am J Med Sci"},{"issue":"1","key":"581_CR16","doi-asserted-by":"publisher","first-page":"12761","DOI":"10.1038\/s41598-020-69691-8","volume":"10","author":"C Lauber","year":"2020","unstructured":"Lauber C, Correia N, Trumpp A, Rieger MA, Dolnik A, Bullinger L, et al. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients. Sci Rep. 2020;10(1):12761. https:\/\/doi.org\/10.1038\/s41598-020-69691-8.","journal-title":"Sci Rep"},{"issue":"11","key":"581_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood.2019003339","volume":"135","author":"MF Bezerra","year":"2020","unstructured":"Bezerra MF, Lima AS, Piqu\u00e9-Borr\u00e0s MR, Silveira DR, Coelho-Silva JL, Pereira-Martins DA, et al. Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. Blood. 2020;135(11):870\u20135.","journal-title":"Blood"},{"key":"581_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","volume":"15","author":"PL Greenberg","year":"2017","unstructured":"Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:60.","journal-title":"J Natl Compr Cancer Netw"},{"key":"581_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41408-018-0074-7","volume":"8","author":"HA Hou","year":"2018","unstructured":"Hou HA, Tsai CH, Lin CC, Chou WC, Kuo YY, Liu CY, et al. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer J. 2018;8:39.","journal-title":"Blood Cancer J"},{"key":"581_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cancergen.2019.07.004","volume":"238","author":"MH Cessna","year":"2019","unstructured":"Cessna MH, Paulraj P, Hilton B, Sadre-Bazzaz K, Szankasi P, Cluff A, et al. Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. Cancer Genet. 2019;238:31\u20136.","journal-title":"Cancer Genet"},{"key":"581_CR21","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1038\/leu.2016.138","volume":"30","author":"A Nazha","year":"2016","unstructured":"Nazha A, Narkhede M, Radivoyevitch T, Seastone DJ, Patel BJ, Gerds AT, et al. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214.","journal-title":"Leukemia"},{"issue":"4","key":"581_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243683","volume":"16","author":"SH Rosenthal","year":"2021","unstructured":"Rosenthal SH, Gerasimova A, Ma C, Li HR, Grupe A, Chong H, et al. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms. PLoS ONE. 2021;16(4): e0243683.","journal-title":"PLoS ONE"},{"issue":"4","key":"581_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/bjh.16891","volume":"192","author":"E Kawata","year":"2021","unstructured":"Kawata E, Lazo-Langner A, Xenocostas A, Hsia CC, Howson-Jan K, Deotare U. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome. Br J Haematol. 2021;192(4):729\u201336.","journal-title":"Br J Haematol"},{"key":"581_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13747","author":"E Kawata","year":"2021","unstructured":"Kawata E, Hedley BD, Chin-Yee B, Xenocostas A, Lazo-Langner A, Hsia CC. Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely? Int J Lab Hematol. 2021. https:\/\/doi.org\/10.1111\/ijlh.13747.","journal-title":"Int J Lab Hematol"},{"issue":"13","key":"581_CR25","doi-asserted-by":"publisher","first-page":"12367","DOI":"10.2147\/OTT.S287944","volume":"1","author":"GG Loscocco","year":"2020","unstructured":"Loscocco GG, Guglielmelli P, Vannucchi AM. Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data. Onco Targets Ther. 2020;1(13):12367\u201382.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"581_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/bjh.16450","volume":"189","author":"B Andr\u00e9asson","year":"2020","unstructured":"Andr\u00e9asson B, Pettersson H, Wasslavik C, Johansson P, Palmqvist L, Asp J. ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients. Br J Haematol. 2020;189(5):913\u20139.","journal-title":"Br J Haematol"},{"issue":"9","key":"581_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fonc.2019.00321","volume":"26","author":"GA Palumbo","year":"2019","unstructured":"Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, Cattaneo D, Iurlo A. The role of new technologies in myeloproliferative neoplasms. Front Oncol. 2019;26(9):321.","journal-title":"Front Oncol"},{"key":"581_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","volume":"17","author":"AS Sperling","year":"2017","unstructured":"Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17:5.","journal-title":"Nat Rev Cancer"},{"key":"581_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;133:1049.","journal-title":"Blood"},{"key":"581_CR30","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209.","journal-title":"N Engl J Med"},{"key":"581_CR31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, G\u00f6nen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079.","journal-title":"N Engl J Med"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-022-00581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-022-00581-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-022-00581-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T10:36:15Z","timestamp":1652351775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-022-00581-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s40291-022-00581-7","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"1 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article (and its Online Supplementary Material).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors declare that they have no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The London Health Sciences Centre Molecular Diagnostics Innovation and Development Fund.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PB, LS, and CH analyzed and interpreted the data, wrote the manuscript, and contributed equally towards this study. CH, IC, BH, and AX contributed in providing patients\u2019 clinical information. MAL, AS, RB, BH, SN, and PB compiled the laboratory data. BS, MAL, HL, PY, JK, and SS contributed towards validation and implementation of the NGS-based assay and manuscript editing. BS and IC planned and executed the study and contributed significantly to writing the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}